Recherche
-
Orphan Drugs: Why the US legislation approves more than the EU?
(International Health Policy Conference, London School of Economics, GB, Londres)Communication dans un congrès avec actes -
Health Technology Assessment Agencies and their economic environment: a European perspective.
(ISPOR 16th Annual European Congress, IE, Dublin)Autre communication scientifique (congrès sans actes - poster - séminaire...) -
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021.
(2017)Document de travail - Pré-publication -
Institutionalizarion of public policies & diffusion of innovation: the case of interventional radiology
(Society for Social Studies of Science Int. Conf., AR, Buenos Aires)Communication dans un congrès avec actes -
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
(The Lancet Neurology. vol. 14, n° 8, pp. 855-866, 2015-07-31)Article de revue -
Naming institution after neologism as marker of the institutionalization of new discipline
(4S Annual Meeting – Society for Social Sciences Studies, AU, Sidney)Communication dans un congrès avec actes -
Orphan Drug Market Exclusivity Extension versus Patent Monopoly
(7th Annual Conference of the American Society of Health Economists, US, Atlanta)Communication dans un congrès avec actes -
The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric and network analysis
(10th Annual Meeting HTAi, KR, Seoul)Communication dans un congrès avec actes -
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
(University of Chicago Press, 2019)Chapitre d'ouvrage -
Institutionnalisation des politiques publiques de santé & diffusion de l’innovation médicale
(Colloque «Science, innovation, technique & société» RT-29 Asso. Fr. Sociologie,, FR, Bordeaux)Communication dans un congrès avec actes